Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9784197 | 0.79 | DGAT1 (0.37) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL4248802 | 0.79 | DGAT1 (0.37) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL8773691 | 0.79 | DGAT1 (0.37) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL3210435 | 0.78 | CA1 (0.37) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL30170510 | 0.77 | SMN1; SMN2 (0.42) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL6207655 | 0.77 | CA12 (0.36) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL28301320 | 0.77 | SMN1; SMN2 (0.42) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL162214 | 0.77 | CA12 (0.36) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL6207363 | 0.77 | CA12 (0.36) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL28190779 | 0.77 | DGAT1 (0.36) | CA12CA14DGAT1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| CN-116102534-A | Covalent PARP PROTACs derivative and application thereof | 四川大学 | 2023-05-12 | — | — | CN | disclosed |
| WO-2023049790-A2 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| EP-4121043-A1 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115443134-A | Conjugates of cell binding molecules and camptothecin analogs | 杭州多禧生物科技有限公司 | 2022-12-06 | — | — | CN | disclosed |
| WO-2021188948-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| CN-113423430-A | Amanitoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2021-09-21 | — | — | CN | disclosed |
| CN-106380398-A | A green synthetic method for tert-butyl bromoacetate | 周亚丽 | 2017-02-08 | — | — | CN | disclosed |
| EP-2812008-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | Cerulean Pharma Inc. (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-2811980-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | Cerulean Pharma Inc. (US) | 2014-12-17 | — | — | EP | disclosed |
| WO-2013115965-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| WO-2013115966-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| WO-2013025337-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| WO-2012050899-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2012-04-19 | — | — | WO | disclosed |
| WO-2012044832-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | FETZER OLIVER S (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | CA12 2957/4885CA14 2860/4885DGAT1 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.